Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Halozyme Therapeutics, Inc. (HALO) had Income from Continuous Operations of $118.09M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$264.86M |
|
$118.09M |
|
$48.40M |
|
$216.46M |
|
$123.33M |
|
$141.53M |
|
$2.29M |
|
$143.83M |
|
$143.83M |
|
$118.09M |
|
|
Income from Continuous Operations |
$118.09M |
$118.09M |
|
$118.09M |
|
$141.53M |
|
$162.12M |
|
123.22M |
|
126.64M |
|
$0.96 |
|
$0.93 |
|
| Balance Sheet Financials | |
$1.26B |
|
$72.82M |
|
$934.50M |
|
$2.20B |
|
$150.38M |
|
$1.51B |
|
$1.56B |
|
$1.71B |
|
$482.27M |
|
$-318.62M |
|
$482.27M |
|
123.17M |
|
| Cash Flow Statement Financials | |
$154.22M |
|
$-90.42M |
|
$-3.32M |
|
$115.85M |
|
$176.33M |
|
$60.48M |
|
$10.67M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.39 |
|
-- |
|
-- |
|
0.76 |
|
3.13 |
|
81.73% |
|
53.44% |
|
53.44% |
|
-- |
|
54.30% |
|
44.59% |
|
$153.27M |
|
-- |
|
-- |
|
-- |
|
0.12 |
|
0.29 |
|
0.87 |
|
103.51 |
|
24.49% |
|
-37.06% |
|
5.38% |
|
5.94% |
|
$3.92 |
|
$1.21 |
|
$1.22 |
|